EMBC
Embecta Corp.
EMBC's fundamentals are mixed, but it looks cheap: trading at 4.4x earnings, less than half its usual 11x. Analysts expect earnings growth, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
EMBC Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Healthy | |
| Strong | |
| Weak |
EMBC's profitability and cash flow are currently healthy, but its revenue and balance sheet are under pressure.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
EMBC PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 3.6x | $6.43 | — |
| Cheap | 4.2x | $6.18 | -3.9% |
| Current | 4.4x | $6.43 | — |
| Fair | 11x | $16.52 | +157% |
| Expensive | 15x | $22.04 | +243% |
Historical ranges are pointers, not guarantees.
EMBC's PE is in its cheap range at 4.4x. If earnings grow as analysts expect, today's price would be 3.6x next year's earnings.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
EMBC Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Growth | |
| Stable | |
| Stable | |
| Limited | |
| Low |
Analysts expect EMBC's earnings to grow, with its revenue and profitability holding steady. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
EMBC Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.81 | +23% |
| Q2 2026 | $1.47 | +3.5% |
| Q1 2026 | $1.89 | +112% |
| Q4 2025 | $2.36 | +138% |
| Q3 2025 | $1.62 | +21% |
| Q2 2025 | $1.42 | +17% |
| Q1 2025 | $0.89 | -27% |
| Q4 2024 | $0.99 | +3.1% |
| Q3 2024 | $1.34 | +9.8% |
EMBC has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
EMBC Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $271.7M | -8.1% |
| Q1 2026 | $221.8M | -14% |
| Q4 2025 | $261.2M | -0.3% |
| Q3 2025 | $264M | -7.7% |
| Q2 2025 | $295.5M | +8.4% |
| Q1 2025 | $259M | -9.8% |
| Q4 2024 | $261.9M | -5.6% |
| Q3 2024 | $286.1M | +1.5% |
EMBC's revenue is shrinking: $272M last quarter, down 8.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 18% | -14 points |
| Q1 2026 | 16% | -8.5 points |
| Q4 2025 | 32% | +21 points |
| Q3 2025 | 21% | +12 points |
| Q2 2025 | 32% | +11 points |
| Q1 2025 | 24% | +11 points |
| Q4 2024 | 11% | -5.4 points |
| Q3 2024 | 9.2% | 0 points |
EMBC has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over EMBC on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
EMBC Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $40.7M | -50% |
| Q1 2026 | $30.6M | -3.5% |
| Q4 2025 | $16.6M | +$23.4M |
| Q3 2025 | $76.7M | +188% |
| Q2 2025 | $80.8M | +$92.6M |
| Q1 2025 | $31.7M | +52% |
| Q4 2024 | -$6.8M | +$9M |
| Q3 2024 | $26.6M | +30% |
EMBC still generates free cash flow, though less than at its 2022 peak: $165M over the past year.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over EMBC on cash flow, with more consistent year-over-year improvement.
EMBC Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -787K shares |
| 1 year | 0% | +17K shares |
| 3 years | +1.6% | +930K shares |
| 5 years | +2.7% | +1.5M shares |
EMBC has 59M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q3 2021 | — |
| Q2 2021 | — |
| Q1 2021 | — |
| Q4 2020 | — |
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over EMBC on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
EMBC Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 4.6x | High |
| Q1 2026 | 3.7x | Elevated |
| Q4 2025 | 3.4x | Elevated |
| Q3 2025 | 4.2x | High |
| Q2 2025 | 5.0x | High |
| Q1 2025 | 6.2x | High |
| Q4 2024 | 7.1x | High |
| Q3 2024 | 6.4x | High |
EMBC's net debt is about 4.6 years of its operating earnings (EBITDA), down from 5.0 years a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has the edge over EMBC on leverage, with a lower net debt burden relative to earnings.
EMBC Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 54.7 | Neutral |
| Stochastic | 81.2 | Overbought |
EMBC's weekly RSI is 55 (neutral) and its Stochastic is 81 (overbought).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
EMBC PE vs Healthcare Sector
| Metric | EMBC | Sector median | Relative |
|---|---|---|---|
| PE | 4.4x | 26x | 83% below |
| PE % | 19 | 43 | 24 pts below |
EMBC is trading at 4.4x earnings, a 83% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
EMBC Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.14 | 4.7% above |
| 20 week MA | $5.08 | 27% above |
| 50 week MA | $7.14 | 9.9% below |
| 100 week MA | $10.4 | 38% below |
| 200 week MA | $14.4 | 55% below |
EMBC has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
EMBC Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2022 | $43.0 | $27.5 | -36% |
| 2023 | $27.5 | $18.9 | -31% |
| 2024 | $18.9 | $20.7 | +9.4% |
| 2025 | $20.7 | $12.0 | -42% |
| 2026 YTD | $12.0 | $6.43 | -46% |
EMBC has finished lower in three of the last four years. It's down 46% so far in 2026.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over EMBC on returns for 2026, with the stronger performance.